Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
Trial Summary
What is the purpose of this trial?
Postural Tachycardia Syndrome (POTS) is the most common autonomic disorder and is estimated to affect 3,000,000 individuals in the United States, with 80-85% of patients being women. The condition is characterized by a rapid increase in heart rate (HR) that occurs on standing, and chronic symptoms of cerebral hypoperfusion leading to lightheadedness, dizziness, and blurred vision. The acute hepatic porphyrias(AHP)are among the diseases that present with autonomic cardiovascular(tachycardia)and neurovisceral symptoms (abdominal pain) among others; they present with acute exacerbations Given that there is available treatment for AHP that change the natural progression of the disease, study focuses to investigate the occurrence of AHP in POTS and determine the clinical and neuro-hormonal characteristic of the POTS subgroup that will likely benefit from AHP screening. This study has one visit that involves, answering some questionnaires, coming to the lab for blood work, genetic testing, and some autonomic function tests. About 50 people will take part in this study.
Research Team
Cyndya Shibao, M.D
Principal Investigator
Vanderbilt University Medical Center
Eligibility Criteria
Inclusion Criteria
Treatment Details
Interventions
- Autonomic Function Tests (Other)
- Blood Work (Other)
- Genetic Testing (Other)
- Questionnaires (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vanderbilt University Medical Center
Lead Sponsor
Jeffrey R. Balser
Vanderbilt University Medical Center
Chief Executive Officer since 2009
MD and PhD from Vanderbilt University
Rick W. Wright
Vanderbilt University Medical Center
Chief Medical Officer since 2023
MD from University of Missouri-Columbia